Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ProAgio - ProDa BioTech

Next Previous
X
Search
Drug Profile

ProAgio - ProDa BioTech

Alternative Names: ACT-50

Latest Information Update: 02 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgia State University
  • Developer Georgia State University; ProDa BioTech
  • Class Antineoplastics; Proteins
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Triple negative breast cancer
  • Phase I Pancreatic cancer

Most Recent Events

  • 20 Aug 2024 Phase-I/II clinical trials in Triple-negative-breast-cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT06460298)
  • 14 Jun 2024 ProDa Biotech plans a phase I/II trial for Triple-negative Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection) (NCT06460298)
  • 29 Dec 2023 ProDa BioTech in collaboration with Georgia State University and University of Alabama plans a phase I/Ib trial for Pancreatic cancer (Metastatic disease, Late-stage disease, Combination therapy, First-line therapy) (IV) (NCT06182072)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top